Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

Pasadena. CA | Posted on August 18th, 2020

The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) – August 27-29, 2020

Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Authors: Edward Gane, et al.
Type: Oral Presentation
Date and Time: August 28, 2020 at 13:30 CEST
European Society of Cardiology (ESC) Congress 2020 – August 29 - September 1, 2020

Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
Authors: Christian Schwabe, et al.
Presenter: Christie M. Ballantyne
Type: Oral Presentation
Date and Time: August 31, 2020 at 10:50 CEST
Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
Authors: Gerald F. Watts, et al.
Type: Oral Presentation
Date and Time: August 31, 2020 at 11:00 CEST
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanomaterials enable dual-mode heating and cooling device: Device could cut HVAC energy use by nearly 20% in the US December 2nd, 2020

Having it Both Ways: A Combined Strategy in Catalyst Design for Suzuki Cross-Couplings December 2nd, 2020

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Possible Futures

Nanomaterials enable dual-mode heating and cooling device: Device could cut HVAC energy use by nearly 20% in the US December 2nd, 2020

Having it Both Ways: A Combined Strategy in Catalyst Design for Suzuki Cross-Couplings December 2nd, 2020

New platform generates hybrid light-matter excitations in highly charged graphene December 2nd, 2020

CsPbBrI2 perovskites with low energy loss for high-performance indoor and outdoor photovoltaics December 1st, 2020

Nanomedicine

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Announcements

Nanomaterials enable dual-mode heating and cooling device: Device could cut HVAC energy use by nearly 20% in the US December 2nd, 2020

Having it Both Ways: A Combined Strategy in Catalyst Design for Suzuki Cross-Couplings December 2nd, 2020

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Events/Classes

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results November 23rd, 2020

Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020 November 13th, 2020

CEA-Leti to Present Latest Results & Insights on 3D Technologies, Power Electronics & Quantum Computing: Institute’s Experts to Host Online Tutorial on Qubit Figures of Merit And Short Course on 3D Sequential Integration November 9th, 2020

Nanobiotechnology

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project